Table 4.
Comparison of patients with HBsAg loss at EOT and in Group 1
| Variables | EOT HBsAg loss group | HBsAg loss in Group 1 | p-value |
|---|---|---|---|
| Gender, male (%) | 5 (83.3%) | 12 (70.6%) | 0.541 |
| Age (years) | 24.8 ± 2.7 | 26.5 ± 5.7 | 0.496 |
| Baseline ALT (U/L) | 249.8 ± 214.0 | 133.6 ± 130.1 | 0.127 |
| Baseline HBV DNA (log10IU/mL) | 4.3 ± 1.5 | 5.8 ± 2.1 | 0.133 |
| Baseline HBsAg (log10IU/mL) | 2.6 ± 0.9 | 2.9 ± 0.6 | 0.399 |
| On-treatment HBsAg decline at week 24 (log10IU/mL) | 1.6 ± 1.4 | 1.2 ± 0.8 | 0.37 |
| On-treatment HBV DNA decline at week 24 (log10IU/mL) | 1.9 ± 1.6 | 3.7 ± 1.6 | 0.041 |
| Duration of IFN (months) | 17.3 ± 4.9 | 14.5 ± 5.2 | 0.254 |
P-value < 0.05 is shown in bold italics